Document Detail


Valsartan: long-term efficacy and tolerability compared to lisinopril in elderly patients with essential hypertension.
MedLine Citation:
PMID:  9385475     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
A total of 501 elderly patients with essential hypertension were randomized to receive valsartan or lisinopril in this one year multi-center, double-blind, parallel group trial. Patients received valsartan 40 mg (n = 334) or lisinopril 2.5 mg (n = 167) daily for 2 weeks with subsequent titration (alone or in combination with hydroclorothiazide), depending on response to treatment. The primary efficacy variable was the percentage of patients with a response, defined as sitting diastolic blood pressure < 90 mmHg or drop of > or = 10 mmHg from baseline. A high percentage of patients responded to treatment in both valsartan and lisinopril groups: 80% for both groups at 12 weeks and 81% and 87%, respectively, at 52 weeks with no statistically significant difference between treatments (12 weeks, p = 0.925; 52 weeks, p = 0.148). More patients on lisinopril experienced drug-related cough (7.5% on valsartan, 17.4% on lisinopril). In 5.4% of lisinopril treated patients, cough led to discontinuation of therapy compared to 0.6% on valsartan. Valsartan 80 mg daily provides comparable short and long-term antihypertensive efficacy to lisinopril in elderly patients with a lower incidence of drug-related cough.
Authors:
A D Bremner; M Baur; P Oddou-Stock; F Bodin
Related Documents :
15133535 - Clinical experience with perindopril in patients nonresponsive to previous antihyperten...
3958825 - Chronic afterload reduction in infants and children with primary myocardial disease.
8750365 - Ramipril decreases chlorthalidone-induced loss of magnesium and potassium in hypertensi...
8438745 - Hemodynamic response to orthostatic stress in the elderly with systolic systemic hypert...
15144255 - Evaluation of level 1 care facilities for vascular patients.
9385955 - Prospective outcome analysis of a protocol for the surgical and rehabilitative manageme...
Publication Detail:
Type:  Clinical Trial; Journal Article; Multicenter Study; Randomized Controlled Trial    
Journal Detail:
Title:  Clinical and experimental hypertension (New York, N.Y. : 1993)     Volume:  19     ISSN:  1064-1963     ISO Abbreviation:  Clin. Exp. Hypertens.     Publication Date:  1997 Nov 
Date Detail:
Created Date:  1998-01-20     Completed Date:  1998-01-20     Revised Date:  2004-11-17    
Medline Journal Info:
Nlm Unique ID:  9305929     Medline TA:  Clin Exp Hypertens     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  1263-85     Citation Subset:  IM    
Affiliation:
Health Centre, Glasgow, Scotland, UK.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Aged
Aged, 80 and over
Angiotensin-Converting Enzyme Inhibitors / adverse effects,  therapeutic use*
Antihypertensive Agents / adverse effects,  therapeutic use*
Dose-Response Relationship, Drug
Double-Blind Method
Female
Humans
Lisinopril / adverse effects,  therapeutic use*
Male
Middle Aged
Tetrazoles / adverse effects,  therapeutic use*
Valine / adverse effects,  analogs & derivatives*,  therapeutic use
Chemical
Reg. No./Substance:
0/Angiotensin-Converting Enzyme Inhibitors; 0/Antihypertensive Agents; 0/Tetrazoles; 137862-53-4/valsartan; 7004-03-7/Valine; 83915-83-7/Lisinopril

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Contribution of nitric oxide to the acute antihypertensive effect of blockers of AT1 angiotensin rec...
Next Document:  Rationale for early treatment with interferon beta-1a in relapsing-remitting multiple sclerosis.